Table 2.
Secondary outcomes for the full cohort and subgroups
| Prophylactic Indomethacin n/N (%) | No Prophylactic Indomethacin n/N (%) | Adjusted OR (95% CI)a For Prophylactic Indomethacin | Interaction p-value | |
|---|---|---|---|---|
| Death by 36 wk PMA | ||||
| Full cohort | 444/2587 (17.2) | 638/5244 (12.2) | 0.80 (0.64–1.01) | |
| Subgroups | ||||
| Gestational Age | 0.75 | |||
| < 26 weeks | 349/1334 (26.2) | 427/1592 (26.8) | 0.82 (0.64–1.04) | |
| ≥ 26 weeks | 95/1253 (7.6) | 211/3652 (5.8) | 0.86 (0.63–1.17) | |
| Birth weight | 0.007 | |||
| < 10th percentile | 91/276 (33.0) | 83/362 (22.9) | 1.32 (0.87–2.01) | |
| ≥ 10th percentile | 353/2311 (15.3) | 555/4882 (11.4) | 0.74 (0.59–0.93) | |
| Sex | 0.09 | |||
| Male | 257/1270 (20.2) | 357/2744 (13.0) | 0.90 (0.70–1.17) | |
| Female | 187/1317 (14.2) | 281/2500 (11.2) | 0.70 (0.53–0.92) | |
| Antenatal corticosteroids | 0.56 | |||
| Treated | 383/2377 (16.1) | 523/4645 (11.3) | 0.79 (0.62–1.00) | |
| Not treated | 61/210 (29.0) | 115/599 (19.2) | 0.90 (0.58–1.40) | |
| PDA treatment after 24 hr | 0.009 | |||
| Treated | 86/542 (15.9) | 196/1895 (10.3) | 1.03 (0.74–1.44) | |
| Not treated | 355/2040 (17.4) | 435/3342 (13.0) | 0.65 (0.51–0.83) | |
| Death by 36 wk PMA or BPD | ||||
| Full cohort | 1404/2587 (54.3) | 2680/5244 (51.1) | 0.87 (0.71–1.05) | |
| Subgroups | ||||
| Gestational Age | 0.42 | |||
| < 26 weeks | 933/1334 (69.9) | 1242/1592 (78.0) | 0.99 (0.78, 1.26) | |
| ≥ 26 weeks | 471/1253 (37.6) | 1438/3652 (39.4) | 0.88 (0.71, 1.10) | |
| Birth weight | 0.88 | |||
| < 10th percentile | 189/276 (68.5) | 288/362 (79.6) | 0.85 (0.55, 1.32) | |
| ≥ 10th percentile | 1512/2311 (65.4) | 2392/4882 (49.0) | 0.87 (0.71–1.06) | |
| Sex | 0.58 | |||
| Male | 742/1270 (58.4) | 1488/2744 (54.2) | 0.83 (0.66–1.05) | |
| Female | 662/1317 (50.3) | 1192/2500 (47.7) | 0.90 (0.72–1.13) | |
| Antenatal corticosteroids | 0.93 | |||
| Treated | 1269/2377 (53.4) | 2373/4645 (51.1) | 0.87 (0.71–1.06) | |
| Not treated | 135/210 (64.3) | 307/599 (51.3) | 0.86 (0.56–1.32) | |
| PDA treatment after 24 hr | 0.88 | |||
| Treated | 365/542 (67.3) | 1290/1895 (68.1) | 0.98 (0.74–1.31) | |
| Not treated | 1036/2040 (50.8) | 1383/3342 (41.4) | 1.00 (0.81–1.24) |
BPD, bronchopulmonary dysplasia; CI, confidence interval; OR, odds ratio; PDA, patent ductus arteriosus; PMA, postmenstrual age. n indicates the number of infants with the outcome and N indicates the total number of infants in each group
Model adjusted for hospital as a random affect and birth weight, gestational age, sex, birth weight < 10th percentile for sex and gestational age, maternal gestational hypertension, antenatal antibiotic exposure, antenatal corticosteroid exposure, rupture of amniotic membranes for greater than 18 hr, delivery by Cesarean section, intubation or cardiopulmonary resuscitation in the delivery room, and invasive mechanical ventilation at 24hr of life as fixed effects.